1. Medtech Insight
  2. >>Business
  3. >>R&D

CDC Chooses Five Laboratories For Pathogen Genomics Network

 
• By Hannah Daniel

The CDC’s $90m funding will be split among five laborites across the US over five years as a part of its pioneering Pathogen Genomics Centers of Excellence Network.

• Source: Shutterstock

The Centers for Disease Control and Prevention (CDC) has named five state laboratories to the Pathogen Genomics Centers of Excellence (PGCoE) Network, a consortium of labs with the goal of piloting new technology and preparing for future pandemics and infectious diseases.

Who will the centers work with?

  • Georgia Department of Public Health: University of Georgia, Georgia Tech Research Institute, Emory University, Augusta University, Georgia State University, and the University of Texas Health Science Center at Houston.

The five labs chosen were the Georgia Department of Public Health, the Minnesota Department of Health, the Massachusetts Department of...

Welcome to Medtech Insight

Create an account to read this article

Already a subscriber?

More from R&D

Synchron Secures $200M Series D, Plans New Brain Interface With ‘Potentially More Applications’

 
• By Marion Webb

Synchron raised $200m in series D funding to support pivotal trials in 2026 as well as commercialization of its Stentrode BCI. It also announced plans for a next-gen high-channel whole-brain interface and a new engineering hub in San Diego.

Makary And Oz Tout Successes At Their Respective Agencies, Say They Are Breaking Down Walls

 
• By Brian Bossetta

Nearly one year into leading their agencies, US FDA Commission Marty Makary and CMS Administrator Mehmet Oz took to the stage together at the Milken Institute’s Future of Health Summit 2025 to highlight what they see as progress and lay out plans for the road ahead.

A Trillion On The Table. Addressing Disparities In Women’s Health Isn’t Just Right. It’s Smart.

 
• By Brian Bossetta

Advocates spanning the spectrum of women’s health met in Manhattan to discuss the gender disparities that remain in healthcare and how public policy can correct them and the enormous ROI investors in women’s health can potentially reap.

Delfi Diagnostics Fragmentomics Lung Cancer Test Nears Key Milestone For FDA Path, Reimbursement

 
• By Marion Webb

Delfi Diagnostics is preparing for pivotal trial results that could support FDA approval and reimbursement for its fragmentomics-based lung cancer screening test. Early data suggest strong potential to improve screening uptake and expand access to early detection.

More from Business

Dexcom Targets Manufacturing Stability, 15-Day Rollout To Restore Margins In 2026

 
• By Shubham Singh

The 15-day sensor, which is initially being introduced within a limited “Warrior” community, will not meaningfully affect 2025 results but will begin to drive both margin expansion and access to lower reimbursement markets the following year.

Smaller Companies Next Frontier for FDA’s Voluntary Improvement Program

 
• By Elizabeth Orr

At the Medical Device Innovation Consortium summit, Cogmedix's Scott Cook discussed the challenges and benefits of transitioning to the FDA's Voluntary Improvement Program, which promotes honesty and opportunities for improvement, leading to faster market access and cost savings.

A Trillion On The Table. Addressing Disparities In Women’s Health Isn’t Just Right. It’s Smart.

 
• By Brian Bossetta

Advocates spanning the spectrum of women’s health met in Manhattan to discuss the gender disparities that remain in healthcare and how public policy can correct them and the enormous ROI investors in women’s health can potentially reap.